We compared the effects of oxaliplatin or oxaliplatin combined with ML264 on constructed CRC xenograft tumors in nude mice to determine whether KLF5 inhibition can restore oxaliplatin sensitivity in vivo. The gene discussed is KLF5; the disease is colorectal carcinoma.